ArticleFrontiers in oncology2022

Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma.

Sunisa Prasopporn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.